Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3089% above fair value
$63.93+2.48 (+4.04%)
Close on Nov 13, 2026Market cap $1.83BP/E 42.1Yield –
Eton Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Eton Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $45.66M, up 6395.4% year over year. For fiscal 2025 it was $3.20M. The highest annual figure on record is $3.20M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.20M | – |
| FY2024 | Dec 31, 2024 | -$1.45M | – |
| FY2023 | Dec 31, 2023 | -$291.00K | – |
| FY2022 | Dec 31, 2022 | -$6.49M | – |
| FY2021 | Dec 31, 2021 | -$1.03M | – |
| FY2020 | Dec 31, 2020 | -$26.76M | – |
| FY2019 | Dec 31, 2019 | -$18.32M | – |
| FY2018 | Dec 31, 2018 | -$10.26M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.46M | – |
| Q2 FY2026 | Jun 30, 2026 | $14.18M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.55M | +552.9% |
| Q4 FY2025 | Dec 31, 2025 | $3.48M | +253.8% |
| Q3 FY2025 | Sep 30, 2025 | -$354.00K | -145.0% |
| Q2 FY2025 | Jun 30, 2025 | -$470.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $543.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $984.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $787.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.66M | -165.5% |
| Q1 FY2024 | Mar 31, 2024 | -$566.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.67M | -226.9% |
| Q3 FY2023 | Sep 30, 2023 | -$357.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $4.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.32M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.31M | -20.1% |
| Q3 FY2022 | Sep 30, 2022 | -$2.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.91M | -190.1% |
| Q4 FY2021 | Dec 31, 2021 | $1.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.30M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.67M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.50M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.68M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.95M | – |
See a number that looks wrong?